Galectin Therapeutics financials
$3.91−0.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$20.1M | -$42.4M | -$38.1M | -$38.4M | -$30.2M | -$23.4M | -$13.4M | -$13.6M | -$16.2M | -$21.5M |
| Net income | -$31.0M | -$47.2M | -$44.8M | -$38.9M | -$30.7M | -$23.6M | -$20.2M | -$15.0M | -$17.5M | -$22.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.48 | $-0.76 | $-0.74 | $-0.65 | $-0.52 | $-0.41 | $-0.39 | $-0.38 | $-0.49 | $-0.76 |
| EBITDA | -$20.1M | -$42.4M | -$38.1M | -$38.4M | -$30.1M | -$23.4M | -$13.4M | -$13.6M | -$16.2M | -$21.5M |
| Operating cash flow | -$23.9M | -$41.8M | -$33.0M | -$31.1M | -$24.3M | -$20.6M | -$10.8M | -$10.2M | -$15.9M | -$16.4M |
| Free cash flow | -$23.9M | -$41.8M | -$33.0M | -$31.1M | — | — | — | — | — | — |
| Diluted shares | 63.9M | 62.3M | 60.2M | 59.4M | 58.5M | 57.0M | 52.2M | 39.4M | 35.5M | 29.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.7M | $15.1M | $25.7M | $18.6M | $39.6M | $27.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $32.7M | $31.9M | $71.7M | $30.0M | $29.0M | $0.00 |
| Total assets | $19.5M | $17.5M | $28.2M | $21.3M | $41.8M | $29.6M |
| Total liabilities | $145.7M | $120.6M | $88.4M | $53.5M | $39.2M | $5.4M |
| Shareholders' equity | -$127.9M | -$104.8M | -$62.0M | -$33.9M | $893.0K | $22.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology